Second pass at: Cagrilintide molecular characteristics and analytical considerations

On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion.

Session topic: PIONEER 6 (N Engl J Med, 2019). Please read it before posting; the discussion is much better when everyone has.

The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.

Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.

I will summarise at the end and the summary will feed the relevant digest page.

I read the opening post twice before replying, because I had assumed the opposite.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.